ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO
SHANGHAI, July 15, 2025 /PRNewswire/ — In the newly released “Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report” by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”), is the […]
ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO Read Post »
Press





